$24.99
-4.6%Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
PGNY โข NASDAQ
| Progyny, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
58.5M | 54.3M | 62M | 30.4M | 65.8M | 46.5M | -8.6M | 661K | -12.5M | |
4.9M | 3.2M | 2.3M | 1.6M | 1.3M | 1.9M | 2.1M | 1.9M | 1.6M | |
-8.1M | -10.5M | 3.7M | -6.6M | -33.3M | -38M | 12K | -1.8M | -3K | |
131.9M | 128.1M | 122.6M | 100.7M | 0.0 | 12.8M | 5.1M | 3M | 1.6M | |
20.2M | 15.7M | 15.6M | 13.8M | 43.5M | 5.6M | 19.8M | -1.8M | 1.3M | |
(0.0) | (40.4M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
2.8M | -11.8M | -17.4M | -59.5M | -51.3M | 7.4M | -20M | 354K | -1.4M | |
210.2M | 179.1M | 188.8M | 80.4M | 26M | 36.2M | -1.5M | 2.3M | -9.5M | |
INVESTING ACTIVITIES | |||||||||
-18.4M | -5.4M | -3.6M | -3.2M | -2.1M | -1M | -3M | -579K | -612K | |
-9.3M | -5.3M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-355M | -170.3M | -429.7M | -163.3M | -111.5M | -104M | (0.0) | (0.0) | (0.0) | |
223.7M | 376.8M | 232.8M | 122.7M | 122.4M | 65M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 200K | 2.5M | 0.0 | |
-159M | (195.8M) | -200.5M | -43.9M | (8.8M) | -40M | -2.8M | (1.9M) | -612K | |
FINANCING ACTIVITIES | |||||||||
-80.4M | -300.3M | 6.1M | 4.2M | 4.3M | 2.7M | 81M | -1.2M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -5.1M | -3.3M | |
-81.7M | -300.3M | (0.0) | (0.0) | (0.0) | (0.0) | -185K | -3.7M | (0.0) | |
-18.9M | -9.6M | -17.2M | -12.1M | -18M | -8.9M | -253K | 65K | 25K | |
-99.4M | -309.9M | -11.1M | -7.9M | -13.7M | -6.2M | 84.5M | -8.7M | 11.8M | |
CASH FLOW SUMMARY | |||||||||
62K | 1K | 1K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-48.1M | 65M | -22.8M | 28.7M | 21.1M | -10.1M | 80.3M | -4.6M | 1.7M | |
162.3M | 97.3M | 120.1M | 91.4M | 70.3M | 80.4M | 127K | 4.7M | 3M | |
114.2M | 162.3M | 97.3M | 120.1M | 91.4M | 70.3M | 80.4M | 127K | 4.7M | |
191.8M | 173.7M | 185.2M | 77.2M | 23.9M | 35.2M | -4.5M | 1.7M | -10.1M |
PGNY - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 27, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 26, 2026 | May 26, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 10, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 13, 2026 | January 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 17, 2025 | December 12, 2025 | 2025 |
Continue your PGNY research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.